From Racheal Crowther’s examination into the ethics of care to SAGG Napoli’s immersive archery installation dissecting ...

Discover the art of fika at this Swedish coffee shop and learn to tell your kanelbullar from your smörgåsar!

Moderna fell to a new 52-week low after some disappointing news. The short explanation is that demand for Moderna's COVID-19 vaccine has plunged since the end of the pandemic. Moderna still has ...

Moderna has lowered 2025 revenue guidance after a tough 2024 coronavirus vaccination season. However, the company aims to launch 10 new products over the next few years -- and that could lead to ...

Ratings for Moderna MRNA were provided by 10 analysts in the past three months, showcasing a mix of bullish and bearish perspectives. The table below provides a concise overview of recent ratings ...

While Sweden’s Ministry of Culture has declared 2006 the Year of Multiculturalism, the Moderna Museet opened ‘The Moderna Exhibition 2006’, an exclusively national salon featuring 49 Swedish artists.

A bad seven-month stretch just got worse for Moderna (NASDAQ: MRNA). The messenger RNA (mRNA) pioneer provided a business and pipeline update at the J.P. Morgan Healthcare Conference on Monday.

There are currently three vaccine candidates moving through the clinical pipeline in human trials right now, and the furthest along is Moderna, which has developed a norovirus vaccine with the ...

Moderna shares will likely remain under scrutiny after plunging nearly 17% Monday as the embattled drug maker slashed its 2025 revenue forecast by $1 billion. The stock broke down from a two ...

Moderna’s mRNA-1403 is a messenger RNA-based trivalent vaccine candidate designed to protect against multiple norovirus genotypes. Moderna provided an update on the status of its trial ...

Moderna Inc. entered the new year on the heels of a worsening stock performance in 2024. The Cambridge drugmaker’s stock dropped even further after lowering its expected revenue range for 2025 ...

Moderna provided updates on key elements of its pipeline, including a next-generation COVID-19 vaccine, an RSV vaccine, a new seasonal flu, and a combination seasonal flu/COVID vaccine. Moderna ...